All In Biotech

Drug Trial Radar · NCT04944992

A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)

A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease

Last checked: Nov 19, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Aug 4, 2021

Primary completion

Oct 19, 2022

Study completion Oct 19, 2022

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD. The primary hypotheses are that efinopegdutide is superior to semaglutide, or that efinopegdutide is superior to semaglutide by at least 10% with respect to mean relative reduction from baseline in liver fat content (LFC) after 24 weeks.

Conditions

  • Nonalcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis

Interventions

  • Efinopegdutide 20 mg/mLDrug

    Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg

  • Semaglutide 1.34 mg/mLDrug

    Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Relative Reduction From Baseline in Liver Fat Content (LFC) Measured by Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF), Evaluated by Blinded Independent Central Review (BICR) After 24 WeeksTime frame: Baseline and up to ~24 Weeks
  2. Percentage of Participants Who Experienced an Adverse Event (AE)Time frame: Up to ~29 weeks
  3. Percentage of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to ~24 weeks

Locations

69 sites in 16 countries. Site status is shown where the registry gives one.

  • Catalina Research Institute, LLC ( Site 1939)

    Montclair, California

  • Sweet Hope Research Specialty, Inc ( Site 1902)

    Hialeah, Florida

  • Floridian Clinical Research, LLC ( Site 1950)

    Miami Lakes, Florida

  • Sensible Healthcare, LLC ( Site 1903)

    Ocoee, Florida

  • Lucas Research, Inc ( Site 1930)

    Morehead City, North Carolina

  • Texas Clinical Research Institute ( Site 1910)

    Arlington, Texas

  • Baylor College of Medicine-Advanced Liver Therapies ( Site 1960)

    Houston, Texas

  • American Research Corporation at Texas Liver Institute ( Site 1920)

    San Antonio, Texas

  • Clinical Trials of Texas, Inc. ( Site 1906)

    San Antonio, Texas

  • IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas ( Site 0107)

    Buenos Aires, Argentina

  • CIPREC-Laboratorio ( Site 0104)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Instituto de Investigaciones Clínicas Mar del Plata ( Site 0101)

    Mar del Plata, Buenos Aires, Argentina

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada ( Site 0105)

    Buenos Aires, Buenos Aires F.D., Argentina

  • Westmead Hospital-Gastroenterology & Hepatology ( Site 0204)

    Westmead, New South Wales, Australia

  • Flinders Medical Centre-Hepatology and Liver Transplant Medicine ( Site 0201)

    Bedford Park, South Australia, Australia

  • Heritage Medical Research Clinic ( Site 0302)

    Calgary, Alberta, Canada

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital F-ENDOCRINOLOGY-DIABETOLOGY ( Site 0401)

    Dijon, Cote-d Or, France

  • centre hospitalier lyon sud-Endocrinologie, Diabète et Nutrition ( Site 0402)

    Pierre-Bénite, Rhone, France

  • Rambam Health Care Campus-Liver disease unit ( Site 0704)

    Haifa, Israel

  • Carmel Hospital-Liver Unit ( Site 0705)

    Haifa, Israel

  • Shaare Zedek Medical Center-Liver Unit ( Site 0703)

    Jerusalem, Israel

  • Rabin Medical Center ( Site 0701)

    Petah Tikva, Israel

  • Sheba Medical Center-The Liver Diseases Center ( Site 0700)

    Ramat Gan, Israel

  • Sourasky Medical Center-Gastroenterology and Liver Disease ( Site 0702)

    Tel Aviv, Israel

  • Azienda Ospedaliero Universitaria ( Site 0803)

    Modena, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Medicine ( Site 0804)

    Verona, Italy

  • Policlinico Umberto I ( Site 0801)

    Rome, Lazio, Italy

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico ( Site 0805)

    Milan, Lombardy, Italy

  • Humanitas-Medicina interna ed Epatologia ( Site 0800)

    Rozzano, Lombardy, Italy

  • Centro de Investigación y Gastroenterología ( Site 0902)

    Cuauhtémoc, Mexico

  • Arké Estudios Clínicos S.A. de C.V.-Gastroenterology-Hepatology ( Site 0906)

    Mexico City, Mexico City, Mexico

  • Medica Sur-Clinica de Enfermedades Digestivas y Obesidad ( Site 0908)

    Mexico City, Mexico City, Mexico

  • Avix Investigación Clinica, S.C. ( Site 0907)

    Monterrey, Nuevo León, Mexico

  • Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion Clinica en Yucatan (

    Mérida, Yucatán, Mexico

  • Auckland City Hospital-Liver Research Unit ( Site 1003)

    Auckland, New Zealand

  • Middlemore Clinical Trials ( Site 1000)

    Auckland, New Zealand

  • Christchurch Hospital-Gastroenterology Research ( Site 1002)

    Christchurch, Canterbury, New Zealand

  • Nasz Lekarz Przychodnie Medyczne ( Site 1105)

    Torun, Kuyavian-Pomeranian Voivodeship, Poland

  • Centrum Medyczne Pratia Warszawa ( Site 1107)

    Warsaw, Masovian Voivodeship, Poland

  • Clinical Medical Research ( Site 1101)

    Katowice, Silesian Voivodeship, Poland

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.